The purpose of this study is to evaluate the role of a urine biomarker panel for diagnosing pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals. Urinary biomarkers are proteins that can be detected in urine and may be indicative of a specific condition or disease. Researchers aim to determine whether the urine biomarker panel is effective in detecting early signs of PDAC. Participants in this study are considered to have a high risk of developing PDAC based on clinical symptoms, imaging studies, and lab samples.